ATE71107T1 - Steroide zur verwendung als mittel gegen krebs und fettsucht, therapeutische zusammensetzungen, die dies enthalten und ihre anwendung zur herstellung einer therapeutischen zusammensetzung. - Google Patents

Steroide zur verwendung als mittel gegen krebs und fettsucht, therapeutische zusammensetzungen, die dies enthalten und ihre anwendung zur herstellung einer therapeutischen zusammensetzung.

Info

Publication number
ATE71107T1
ATE71107T1 AT87107411T AT87107411T ATE71107T1 AT E71107 T1 ATE71107 T1 AT E71107T1 AT 87107411 T AT87107411 T AT 87107411T AT 87107411 T AT87107411 T AT 87107411T AT E71107 T1 ATE71107 T1 AT E71107T1
Authority
AT
Austria
Prior art keywords
preparation
cancer
therapeutic composition
steroids
compositions containing
Prior art date
Application number
AT87107411T
Other languages
English (en)
Inventor
Arthur G Schwartz
Marvin Louis Lewbart
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of ATE71107T1 publication Critical patent/ATE71107T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT87107411T 1986-05-21 1987-05-21 Steroide zur verwendung als mittel gegen krebs und fettsucht, therapeutische zusammensetzungen, die dies enthalten und ihre anwendung zur herstellung einer therapeutischen zusammensetzung. ATE71107T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86711286A 1986-05-21 1986-05-21
EP87107411A EP0246650B1 (de) 1986-05-21 1987-05-21 Steroide zur Verwendung als Mittel gegen Krebs und Fettsucht, therapeutische Zusammensetzungen, die dies enthalten und ihre Anwendung zur Herstellung einer therapeutischen Zusammensetzung

Publications (1)

Publication Number Publication Date
ATE71107T1 true ATE71107T1 (de) 1992-01-15

Family

ID=25349110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87107411T ATE71107T1 (de) 1986-05-21 1987-05-21 Steroide zur verwendung als mittel gegen krebs und fettsucht, therapeutische zusammensetzungen, die dies enthalten und ihre anwendung zur herstellung einer therapeutischen zusammensetzung.

Country Status (12)

Country Link
EP (1) EP0246650B1 (de)
JP (1) JP2566574B2 (de)
AT (1) ATE71107T1 (de)
AU (1) AU601184B2 (de)
CA (1) CA1329195C (de)
DE (1) DE3775617D1 (de)
DK (1) DK173168B1 (de)
ES (1) ES2039373T3 (de)
GR (1) GR3003769T3 (de)
IE (1) IE60027B1 (de)
NO (1) NO173278C (de)
PT (1) PT84911B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2973031B2 (ja) * 1990-08-29 1999-11-08 ヒューマネティックス コーポレーション 減量を促進するための置換δ５−アントロステンを含む医薬
US5424463A (en) * 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5585371A (en) * 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
JPH0684398B2 (ja) * 1990-08-31 1994-10-26 雪印乳業株式会社 新規なアンドロステン誘導体及びそれを用いる６‐アルキルカルボニルオキシ‐１４α‐ヒドロキシ‐アンドロスト‐４，６‐ジエン‐３，１７‐ジオンの製造法
WO2002028880A2 (en) * 2000-10-06 2002-04-11 Aeson Therapeutics Inc. Compounds useful for treating hypertriglyceridemia
EP1499338A4 (de) * 2002-05-01 2008-06-18 Arthur Schwartz 7-hydroxy-16alpha-fluor-5-androsten-17-one und 7-hydroxy-16alpha-fluor-5-androstan-17-one und ihre derivate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1314870C (en) * 1983-08-02 1993-03-23 Arthur G. Schwartz Steroids useful as anti-cancer, anti-obesity, anti-hyperglycemic, anti-autoimmune and anti-hypercholesterolemic agents
DE3666437D1 (en) * 1985-08-02 1989-11-23 Research Corp Steroids useful as anti-cancer, anti-obesity, anti-hyperglycemic, anti-autoimmune and anti-hyper-cholesterolemic agents
JP2920854B2 (ja) * 1991-08-01 1999-07-19 富士通株式会社 ビィアホール構造及びその形成方法

Also Published As

Publication number Publication date
AU7329687A (en) 1987-11-26
DK173168B1 (da) 2000-02-28
DE3775617D1 (de) 1992-02-13
EP0246650A1 (de) 1987-11-25
JP2566574B2 (ja) 1996-12-25
DK259387A (da) 1987-11-22
JPS62283993A (ja) 1987-12-09
GR3003769T3 (de) 1993-03-16
IE871312L (en) 1987-11-21
AU601184B2 (en) 1990-09-06
PT84911A (en) 1987-06-01
NO173278B (no) 1993-08-16
DK259387D0 (da) 1987-05-21
NO173278C (no) 1993-12-01
PT84911B (pt) 1990-02-08
IE60027B1 (en) 1994-05-18
NO872115D0 (no) 1987-05-20
CA1329195C (en) 1994-05-03
EP0246650B1 (de) 1992-01-02
ES2039373T3 (es) 1993-10-01
NO872115L (no) 1987-11-23

Similar Documents

Publication Publication Date Title
ES8706717A1 (es) Metodo de preparar esteroides
KR900700486A (ko) 신규한 벤조피리도 피페리딘, 피페리딜리덴 및 피페라진 화합물, 조성물, 제조방법 및 이용방법
CA2124932A1 (en) Sex steroid activity inhibitors
CA2259621A1 (en) Isocoumarin derivatives and their use in medicines
FR2506156A1 (fr) Compositions cosmetiques contenant des derives hydroxyles du dibenzoylmethane et leur utilisation pour la protection de l'epiderme humain contre les rayons ultraviolets
NO175617C (no) Fremgangsmåte ved fremstilling av blandinger som omfatter vandig etanol, for ökning av transdermal ström
GR3023938T3 (en) 3',5'-ditertbutyl-4'-hydroxyflavones, method for their preparation and pharmaceutical compositions with an antioxidant and antivasoconstricting activity
ATE116657T1 (de) 7-keto- und 7-hydroxy-androsta-3,5-dien-3- carbonsäure derivate.
DE3415413A1 (de) Melanin-inhibitor
ATE71107T1 (de) Steroide zur verwendung als mittel gegen krebs und fettsucht, therapeutische zusammensetzungen, die dies enthalten und ihre anwendung zur herstellung einer therapeutischen zusammensetzung.
FR2706454B1 (fr) Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant.
AU1498295A (en) MDR resistance treatment
ATE193531T1 (de) Phenyl-carboxamide-isoxazole-derivate und salze, verfahren zu ihrer herstellung ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen die sie enthalten
DE60043295D1 (de) Chromanol glycoside zur behandlung von durch ultraviolettes licht verursachten dermopathien
EP0278384A3 (de) Alkohole und Ether mit Cyclododecyl- und Cyclododecenylgruppen, deren Herstellung und Verwendung als Duftstoffe
EP0270046A3 (en) Pharmaceutical composition for treatment of cataract
DE223671T1 (de) Arzneimittel mit synergistischer entzuendungshemmender wirkung auf der basis eines corticosteroiden und eines beta-agonisten.
CA1069054A (en) 4-pyridoxinate derivatives as light screening agents
ZA921735B (en) Indane derivatives
KR970065495A (ko) 1, 25-디하이드록시-16, 22, 23-트리스데하이드로-콜레칼시페롤 유도체
ATE56709T1 (de) Phenylpyrazinderivate, verfahren zu deren herstellung, pharmazeutische zusammensetzung und verwendung.
ES481207A1 (es) Un procedimiento para l preparacion de derivados de benzoci-cloheptapiridinas.
ATE49003T1 (de) Pregnane derivate, verfahren zu ihrer herstellung und pharmazeutische zusammenstellungen, die sie enthalten.
DE69306513D1 (de) Neue kardioaktive Zyklopentaperhydrophenanthrene-17-beta-(hydroxy oder alkoxy)-17-alpha-(aryl oder heterozyklyl)-3-beta Derivate, ein Verfahren zu ihrer Herstellung und pharmazeutische Präparate davon
DE3762341D1 (de) Chinolinderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende zubereitungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties